Given the serious side effects of CAR-T cells targeting healthy tissue [102, 103], DLL3 is highly restricted to SCLC with a neglectable expression in the normal adult tissues, making it an ideal target for cancer immunotherapy [104]. The gene discussed is DLL3; the disease is small cell lung carcinoma.